bifeprunox
≈ 2 min read
Names in other languages
- labifeprunoxum
- Polskibifeprunoks
- shBifeprunoks
- СрпскиBifeprunoks
- TürkçeBifeprunoks
- Englishbifeprunox
- فارسیبیفپرونوکس
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Bifeprunox (INN; code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D 2 receptor agonism with serotonin receptor agonism. It was under development for the treatment of schizophrenia, psychosis, and Parkinson's disease.
In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects. An NDA for Bifeprunox was filed with the U.S. Food and Drug Administration in January 2007. The FDA rejected the application in August 2007.
In June 2009, Solvay and Wyeth decided to cease development because "efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia."
Bifeprunox (INN; code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D 2 receptor agonism with serotonin receptor agonism. It was under development for the treatment of schizophrenia, psychosis, and Parkinson's disease.
In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects. An NDA for Bifeprunox was filed with the U.S. Food and Drug Administration in January 2007. The FDA rejected the application in August 2007.
In June 2009, Solvay and Wyeth decided to cease development because "efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia."
See also
List of investigational antipsychotics List of investigational bipolar disorder drugs List of investigational Parkinson's disease drugs Aripiprazole Pardoprunox
Text derived from https://en.wikipedia.org/w/index.php?oldid=1357686890 under CC BY-SA 4.0; modifications have been made.